| Title |
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
|
|---|---|
| Published in |
Journal of Hepatology, April 2017
|
| DOI | 10.1016/j.jhep.2017.03.021 |
| Pubmed ID | |
| Authors |
European Association for the Study of the Liver, Pietro Lampertico, Kosh Agarwal, Thomas Berg, Maria Buti, Harry L.A. Janssen, George Papatheodoridis, Fabien Zoulim, Frank Tacke |
| Abstract |
Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and migration. This CPG presents updated recommendations for the optimal management of HBV infection. Chronic HBV infection can be classified into five phases: (I) HBeAg-positive chronic infection, (II) HBeAg-positive chronic hepatitis, (III) HBeAg-negative chronic infection, (IV) HBeAg-negative chronic hepatitis and (V) HBsAg-negative phase. All patients with chronic HBV infection are at increased risk of progression to cirrhosis and hepatocellular carcinoma (HCC), depending on host and viral factors. The main goal of therapy is to improve survival and quality of life by preventing disease progression, and consequently HCC development. The induction of long-term suppression of HBV replication represents the main endpoint of current treatment strategies, while HBsAg loss is an optimal endpoint. The typical indication for treatment requires HBV DNA >2000 IU/ml, elevated ALT and/or at least moderate histological lesions, while all cirrhotic patients with detectable HBV DNA should be treated. Additional indications include the prevention of mother-to-child transmission in pregnant women with high viremia and prevention of HBV reactivation in patients requiring immunosuppression or chemotherapy. The long-term administration of a potent nucleos(t)ide analogue with high barrier to resistance, i.e. entecavir, tenofovir disoproxil or tenofovir alafenamide, represents the treatment of choice. Pegylated interferon-alfa can be also considered in mild to moderate chronic hepatitis B. Combination therapies are not generally recommended. All treated and untreated patients should be monitored for treatment response and adherence, and the risk of progression and development of complications. HCC remains the major concern for treated chronic hepatitis B patients. Several subgroups of patients with HBV infection require specific focus. Future treatment strategies to achieve "cure" of disease and new biomarkers are discussed. |
X Demographics
The data shown below were collected from the profiles of 134 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 17 | 13% |
| United States | 12 | 9% |
| United Kingdom | 7 | 5% |
| India | 4 | 3% |
| Mexico | 4 | 3% |
| Colombia | 3 | 2% |
| Switzerland | 3 | 2% |
| France | 2 | 1% |
| Brazil | 2 | 1% |
| Other | 20 | 15% |
| Unknown | 60 | 45% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 101 | 75% |
| Practitioners (doctors, other healthcare professionals) | 17 | 13% |
| Scientists | 13 | 10% |
| Science communicators (journalists, bloggers, editors) | 3 | 2% |
Mendeley readers
The data shown below were compiled from readership statistics for 1,741 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| Germany | 1 | <1% |
| Italy | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 1737 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 171 | 10% |
| Student > Master | 170 | 10% |
| Student > Bachelor | 167 | 10% |
| Other | 148 | 9% |
| Student > Ph. D. Student | 138 | 8% |
| Other | 331 | 19% |
| Unknown | 616 | 35% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 620 | 36% |
| Biochemistry, Genetics and Molecular Biology | 114 | 7% |
| Immunology and Microbiology | 84 | 5% |
| Nursing and Health Professions | 51 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 50 | 3% |
| Other | 157 | 9% |
| Unknown | 665 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 451. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 February 2024.
All research outputs
#61,975
of 25,593,129 outputs
Outputs from Journal of Hepatology
#19
of 6,310 outputs
Outputs of similar age
#1,378
of 324,457 outputs
Outputs of similar age from Journal of Hepatology
#2
of 99 outputs
Altmetric has tracked 25,593,129 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,310 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 324,457 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 99 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.